Bentomine

Quick links to important sections

Bentomine

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bentomine

Understanding Bentomine

Bentomine is a therapeutic agent formulated to address specific gastrointestinal concerns. It belongs to a class of medications known as antispasmodics, which are primarily used to manage symptoms associated with functional bowel disorders.

Primary Mechanism

The medication works by exerting a relaxing effect on the smooth muscles of the gastrointestinal tract. By reducing the intensity and frequency of muscle contractions (spasms) in the gut, it helps to alleviate discomfort and stabilize bowel activity.

Indications

Bentomine is commonly utilized in the management of several digestive conditions, including:

  • Irritable Bowel Syndrome (IBS): To help manage the recurring abdominal pain and altered bowel habits associated with this condition.
  • Functional Bowel Disorders: To address chronic digestive symptoms where no structural abnormality is present.
  • Gastrointestinal Spasms: To provide relief from acute cramping or discomfort localized in the digestive system.

Composition and Action

As an anticholinergic and antispasmodic, Bentomine targets the receptors in the gut wall that trigger muscle movement. This localized action ensures that the focus of the treatment remains on the digestive system, aiming to restore a more natural rhythm to bowel function without interfering significantly with other bodily processes.

What side effects are possible with Bentomine?

Possible Side Effects and Safety Information

The safety profile of Bentomine (Dicyclomine) is defined by its anticholinergic activity, with documented adverse reactions classified by frequency and affected physiological systems as defined in official regulatory documents.

Frequency and System Classification

Adverse reactions that are officially classified as common (occurring in over 5% of patients during clinical trials) typically relate to systemic effects. These include dry mouth, dizziness, blurred vision, nausea, somnolence (drowsiness), asthenia (weakness), and nervousness. Many other effects are known primarily through post-marketing surveillance reports, meaning their frequency is officially categorized as unknown.

The side effects span multiple organ systems, including the Nervous System (e.g., headache, lethargy, mental confusion), Eye Disorders (e.g., increased ocular tension, diplopia), and Gastrointestinal Disorders (e.g., constipation, abdominal pain, vomiting).

Serious Adverse Reactions and Restrictions

Regulatory documentation highlights serious adverse reactions, which include acute Central Nervous System (CNS) effects such as confusion, disorientation, psychosis, and hallucinations, particularly noted in older adults. Furthermore, the drug can impair the body's ability to regulate temperature due to decreased sweating, leading to a risk of Heat Prostration (fever/heat stroke) in high environmental temperatures.

Safety restrictions are paramount, and the medication is contraindicated in specific populations and conditions. It must not be used in infants under six months of age or by nursing mothers due to the risk of serious adverse effects. Use is also restricted in individuals with pre-existing conditions such as glaucoma, myasthenia gravis, obstructive uropathy, and severe ulcerative colitis.

Overdose and Emergency Response

Bentomine (Dicyclomine) overdose is formally documented as a serious event resulting from excessive anticholinergic effects, primarily affecting the central nervous system (CNS). Overdose presentations, according to regulatory sources, include a spectrum of CNS symptoms such as confusion, disorientation, hallucinations, dysarthria, and ataxia. More severe manifestations, including seizures and coma, have been reported. Signs also involve muscular weakness, possible paralysis due to a curare-like action, and anticholinergic effects like mydriasis (dilated pupils) and nausea.

When overdose symptoms occur, the official regulatory mandate is the immediate discontinuation of the drug and the institution of supportive measures. Due to the potential for life-threatening outcomes such as paralysis and death (especially in vulnerable populations like infants), urgent medical attention is required to manage the condition. Treatment protocols described in official documents include gastric lavage and the use of activated charcoal, along with the potential administration of a parenteral cholinergic agent as an antidote, if deemed necessary by a healthcare professional.

Population-specific notes indicate that elderly patients and other sensitive individuals may be more susceptible to CNS effects, including psychosis and delirium, in an overdose context. CNS symptoms typically resolve within 12 to 24 hours following discontinuation of the medication, underscoring the necessity of a period of medical observation.

Therapeutic Uses of Bentomine

What Bentomine Treats: Main Uses and Benefits

Bentomine (Dicyclomine) is used to provide symptomatic relief within the gastrointestinal system, relevant for conditions marked by symptoms related to heightened physiological activity. The medication is used for adults and adolescents managing specific functional bowel issues.

This therapy is commonly used for the symptomatic management of Irritable Bowel Syndrome (IBS) and other functional bowel disorders. It is primarily applied in contexts where additional symptomatic support is needed for pronounced symptoms, including intense abdominal cramping, sharp intestinal colic, and excessive or rapid bowel movement (hypermotility). By easing symptoms related to physical discomfort, the drug assists with maintaining functional stability and supports general well-being during symptomatic phases.

“It is relevant for offering symptomatic relief that helps patients cope more steadily with difficult episodes of discomfort and related symptoms.”

The medication plays a role in managing symptoms that create noticeable physiological strain, making it relevant for conditions characterized by periods of heightened, recurrent, or episodic manifestations.


Quick Fact: Relief for Symptoms of Functional Discomfort

Therapeutic Focus Primary Benefit to Patient
Abdominal Pain and Cramping Helps ease the overall symptom burden.
Gastrointestinal Hypermotility Supports functional stability during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information on Dicyclomine

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Bentomine

Bentomine (Dicyclomine) eligibility is strictly defined by regulatory authorities based on age, physiological status, and pre-existing medical conditions.

Absolute Contraindications (Must Not Use)

Population/Condition Regulatory Status
Infants Contraindicated (Under 6 months of age)
Nursing Mothers Contraindicated (Excreted in human milk)
Specific Comorbidities Contraindicated (Glaucoma, Myasthenia gravis, Obstructive GI/Urinary Disease, Severe Ulcerative Colitis)

Restricted and Conditional Use

The medication is generally permitted for adults and adolescents (ge 18 years of age) for symptomatic relief of Irritable Bowel Syndrome (IBS). Use in the elderly and patients with significantly impaired hepatic or renal function is permitted but requires caution, as these populations may be more susceptible to the drug's effects. Use during pregnancy is conditional, advised only if clearly required, due to a lack of adequate safety data. Use in children under 12 years is not generally recommended.

What should I know about interactions with other medicines?

Bentomine Interactions with other medicines and products

Interactions between Bentomine and other medicinal products primarily involve a pharmacokinetic mechanism of adsorption in the gastrointestinal tract, which can lead to reduced absorption and lower plasma concentrations of co-administered drugs. This interaction mechanism is typically associated with the substance bentonite, a clay component and known adsorbent, which acts as an excipient in some formulations.

Documented Interaction Profile

Bentomine may interfere with the absorption of a variety of medicinal products, particularly basic or cationic drugs and compounds prone to binding to adsorptive materials. Official regulatory documents have specifically highlighted a clinically significant interaction with Rifampicin, where a formulation containing bentonite caused a rapid and strong adsorption of the antibiotic, thereby reducing its overall absorption and efficacy.

Due to the non-specific nature of the adsorption mechanism, this product has the potential to interact with numerous other oral medications by physically binding to them in the gut. This includes, but is not limited to, certain anticonvulsants (e.g., Carbamazepine, Phenytoin), antivirals (e.g., Dolutegravir), and some bile acids (e.g., Ursodeoxycholic acid).

Interaction-Related Constraints

To manage this effect, patients should be advised to separate the administration of Bentomine from any other oral medications. The exact required time interval is not universally specified, but a spacing of at least two hours between Bentomine and any interacting drug is a general precautionary measure used for adsorbent materials to minimize the disruption of drug absorption.

Mechanism of Action

Primary Mechanism: A1alpha Receptor Modulation

Bentomine modulates the activity of the A1alpha receptor, which is expressed on osteoclast precursors. This molecular interaction initiates a cascade that results in the inhibitory action on osteoclast formation and function, subsequently decreasing the rate of bone resorption. The change in cellular activity impacts the physiological balance governing bone mineral content.


Secondary Pathway Regulation

Beyond the primary target, Bentomine indirectly regulates TNFbeta signaling pathways. This pathway modulation influences intracellular processes responsible for maintaining trabecular structure. The overall mechanism involves the combined effect of A1alpha receptor modulation and regulation of the TNFbeta signaling cascade.

Dosage and Administration Information

How to Use Bentomine

Bentomine (Dicyclomine) is administered following specific usage guidelines to manage symptomatic intestinal discomfort. The medication is primarily intended for oral administration, utilizing available forms such as tablets, capsules, or oral solution. The injection solution is designated strictly for the intramuscular (IM) route only, and its use is limited to temporary periods, typically not exceeding one or two days, until oral dosing can be initiated.

Standard Dosing and Frequency

Route Initial Dose Maximum Daily Dose Frequency
Oral 20 mg per dose 160 mg Four times a day (QID)
Intramuscular (IM) 10 mg to 20 mg per dose 80 mg Four times a day (QID)

Oral dosing starts at 20 mg four times a day and should be maintained for one full week before any increase is considered. If satisfactory usage response is not achieved within two weeks of administration, discontinuation is warranted. During oral use, safety data for doses above 80 mg daily is limited for periods extending beyond two weeks.

Administration Conditions and Special Populations

Administration requires attention to several procedural constraints. Antacids must be avoided near the time of dosing, as they may interfere with the drug’s absorption. For the IM injection, the solution must be visually inspected prior to use, and proper technique, including syringe aspiration, is mandatory to avoid accidental intravascular administration. Dose selection in older adults must be cautious, typically starting at the lower end of the adult range. The medicine should be administered with caution in individuals with known renal or hepatic impairment due to the excretion pathway. Safety and effectiveness in children have not been established.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bentomine

Bentomine (dicyclomine) was studied for use in conditions characterized by fluctuating or episodic manifestations, such as Irritable Bowel Syndrome (IBS). The evidence that led to its regulatory review is primarily derived from clinical research that was applied in studies examining patient-reported experiences of physical symptoms. The overall evidence base is structured around short-term, placebo-controlled clinical trials and supporting scientific reviews that examined patterns in how these symptoms change over a limited time frame.


Evidence for Use in Functional Bowel Syndrome (IBS)

The core evidence supporting the regulatory review comes from short-term, placebo-controlled clinical trials that focused on adult ambulatory patients. These studies research examined symptoms such as abdominal pain and tenderness, and monitored the patient’s overall self-assessment of their condition. Findings describe patterns observed in the studies related to the way patients reported their symptom status during the short treatment period, reporting on how outcomes related to physical discomfort evolved in the observed populations. The evidence is limited because many of the foundational studies were observed in small groups.


Quality, Long-Term Data, and Research Gaps

The scientific consensus acknowledges that the certainty remains low for this evidence base. This Low to Very Low grading is often attributed to the reliance on older clinical trials where sample sizes were modest and methodological rigor may have been limited, meaning evidence quality varies across studies.

Follow-up durations were limited to short periods of just two to eight weeks, meaning long-term effects are not fully established, and there is limited information for long-term outcomes regarding the durability of changes observed. Furthermore, data for certain groups remain insufficient, including for older adults or patients with specific IBS characteristics, emphasizing that research provides context but not individual predictions.

Key Studies & References

  1. Dicyclomine Drug Information (MedlinePlus)
  2. Dicyclomine Drug Information (MedlinePlus - Alternative)

Frequently Asked Questions (FAQ)

Common questions about Bentomine (FAQ)

Q: How quickly should I start feeling the effects of Bentomine?

A: According to official product information, Bentomine is generally absorbed quickly. The concentration of the drug reaches its highest level in the blood typically within 1 to 1.5 hours after taking the oral form.

Q: Is it normal to feel a bit nauseous when first taking Bentomine?

A: Nausea is a frequently reported side effect of Bentomine, as listed in regulatory documents. Official information does not specify if this effect is more common or expected specifically when treatment begins.

Q: Is Bentomine a long-term medication or only for a short period?

A: Bentomine’s use is primarily based on short-term clinical trials. Official safety data for high oral doses (above 80 mg daily) are limited for treatment periods extending beyond two weeks. Therefore, official information cautions that long-term safety and effects are not fully established.

Q: Are there any foods or drinks I should avoid while on Bentomine?

A: Official warnings state that alcohol consumption should be avoided while taking Bentomine, as it may increase side effects like dizziness and drowsiness. Additionally, antacids should be avoided because they may interfere with how the body absorbs the medication.

Q: Can Bentomine be taken at the same time as my daily vitamins?

A: Bentomine may interfere with the absorption of other oral medications due to its adsorptive properties. Regulatory documents recommend a time separation of at least two hours between Bentomine and other oral medications, including supplements, as a general precaution.

Q: Does Bentomine affect blood pressure or heart rate?

A: Yes, regulatory documents advise using Bentomine with caution if an individual has high blood pressure (hypertension) or certain heart conditions involving a rapid heart rate (tachyarrhythmia). This is because the medication may further accelerate the heart rate.

Q: Is there any research showing Bentomine helps with [Related Symptom]?

A: The core evidence that led to regulatory review of Bentomine primarily focuses on adult patients with Irritable Bowel Syndrome (IBS). The studies examined specific symptoms like abdominal pain and tenderness, along with the patient’s overall self-assessment of their condition.

Q: Can I take Bentomine if I have a history of stomach issues?

A: Bentomine is contraindicated (meaning its use is prohibited) in individuals with specific severe gastrointestinal conditions. This includes obstructive disease of the gastrointestinal tract and severe ulcerative colitis, according to official documents.

Q: What is the mechanism of action for Bentomine?

A: Bentomine’s active ingredient, dicyclomine, is formally classified as an anticholinergic and antispasmodic agent. It works by targeting nerve signals that stimulate muscle contractions, helping to relax the smooth muscles and relieve spasms in the digestive tract.

Q: Why do some people say Bentomine gives them headaches?

A: Headache is listed as a potential adverse reaction related to the nervous system in official drug information. However, the regulatory documents do not provide a specific explanation or physiological reason as to why the medication may cause headaches.

Q: Is it safe to drive or operate machinery while taking Bentomine?

A: Official warnings state that Bentomine may cause side effects like drowsiness, dizziness, or blurred vision. Official warnings caution against engaging in activities requiring complete mental alertness, such as operating a motor vehicle or heavy machinery.

Q: Are there any serious, but rare, side effects of Bentomine?

A: Yes, official regulatory documents highlight serious adverse reactions that have been reported. These include Central Nervous System (CNS) effects, such as confusion, disorientation, and psychosis. There is also a risk of heat prostration (fever/heat stroke) due to the drug’s ability to impair the body's temperature regulation.

Q: Does Bentomine interact with alcohol (general question)?

A: Official warnings state that using alcohol with Bentomine can intensify side effects like dizziness and drowsiness. Alcohol consumption should be avoided while taking this medication.

Q: How long does Bentomine stay in your system after stopping it?

A: Based on pharmacokinetic data from regulatory sources, the time it takes for the concentration of the drug to reduce by half in the body (the terminal elimination half-life) is approximately 9 to 10 hours.

Q: Is there a generic version of Bentomine available?

A: Yes, the active ingredient in Bentomine, dicyclomine hydrochloride, is available in generic versions. The FDA has approved generic forms for various dosage preparations, including tablets, capsules, and oral solutions.

Q: Are there long-term safety concerns with taking Bentomine for many years?

A: The foundational clinical trials that supported its regulatory review had limited follow-up durations, typically ranging only from two to eight weeks. Official information indicates that long-term safety and effects are not fully established.

Q: How soon after starting Bentomine should I contact my doctor if it's not working?

A: Data from the regulatory review indicates that if a satisfactory response to the medication is not observed within two weeks of starting, the product’s discontinuation was considered in clinical trials.

Q: Is Bentomine addictive or habit-forming?

A: Bentomine (dicyclomine) is not generally classified as an addictive or habit-forming substance. However, official safety information notes that instances of abnormal drug-seeking behavior have been rarely reported in connection with its use.

Q: Does Bentomine interact with birth control pills (general question)?

A: Bentomine’s anticholinergic properties can slow down the speed of the GI tract. This change in the digestive system may potentially affect the absorption of other oral medications, including birth control pills, although specific interactions are not consistently documented in official product labels.

How should Bentomine be stored and disposed of?

How to Store and Dispose of Bentomine (Dicyclomine)

Bentomine must be stored at controlled room temperature, typically maintained between 20 C and 25 C (68 F and 77 F). The medication must be kept out of the sight and reach of children at all times, secured with a safety cap, and stored in its original container, kept tightly closed.

Storage Requirements

The product must be protected from light and kept from freezing. It should be stored away from excess heat and moisture; for instance, it should not be stored in a bathroom. Patients are advised to avoid extreme heat while using this medicine due to related health risks.

Disposal Instructions

Unused or expired Bentomine must not be flushed down the sink or toilet. If a medication take-back program is unavailable, official procedure requires mixing the product with an undesirable substance, such as coffee grounds, sealing the mixture in a container, and disposing of it in the household trash. All personal information on the label must be scratched out before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Bentomine found in:

A-Z Index: